Histone deacetylase inhibitors as radiosensitisers: Effects on DNA damage signalling and repair

British Journal of Cancer

Volumn 108, Issue 4, 2013, Pages 748-754

  Groselj, B ^a   Sharma, N L ^a   Hamdy, F C ^a   Kerr, M ^a   Kiltie, A E ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

clinical trials; DNA damage signalling; DNA repair; histone deacetylase inhibitors

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ABEXINOSTAT; BEVACIZUMAB; BUTYRIC ACID; CAPECITABINE; CISPLATIN; DOUBLE STRANDED DNA; DOXORUBICIN; ENTINOSTAT; FLUOROURACIL; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MOCETINOSTAT; PACLITAXEL; PANOBINOSTAT; PEMETREXED; RADIOSENSITIZING AGENT; ROMIDEPSIN; TEMOZOLOMIDE; VALPROIC ACID; VORINOSTAT;

ANAPLASTIC THYROID CANCER; ARTICLE; BRAIN METASTASIS; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COLON CANCER; DIGESTIVE SYSTEM CANCER; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; DNA STRAND BREAKAGE; GLIOBLASTOMA; GLIOMA; HOMOLOGOUS RECOMBINATION; HUMAN; IRRADIATION; LUNG NON SMALL CELL CANCER; MELANOMA CELL; OROPHARYNX CANCER; OSTEOSARCOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIZATION; RHABDOMYOSARCOMA; SARCOMA; SIGNAL TRANSDUCTION; STEREOTACTIC RADIOSURGERY; UTERINE CERVIX CANCER;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DNA DAMAGE; DNA REPAIR; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASMS; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION;

EID: 84875223519     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.21     Document Type: Article

References (35)

1. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford J, Buggy J (2007) HDAC inhibitor PCI-24781 decreases
2. RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA 104(49): 19482-19487.
3. Blattmann C, Oertel S, Ehemann V, Thiemann M, Huber P, Bischof M, Witt O, Deubzer H, Kulozik A, Debus J, Weber K (2010) Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 78(1): 237-245.
4. Bratland A, Dueland S, Hollywood D, Flatmark K, Ree AH (2011) Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. Radiat Oncol 6: 33
5. Candelaria M, Cetina L, Perez-Cardenas E, de la Cruz-Hernandez E, Gonzalez-Fierro A, Trejo-Becerril C, Taja-Chayeb L, Chanona J, Arias D, Duenas-Gonzalez A (2010) Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer. Eur J Gynaecol Oncol 31(4): 386-391.
6. Chen X, Wong P, Radany E, Wong J (2009) HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm 24(6): 689-699.
7. Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang S, Harari P (2005) Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62(1): 223-229.
8. Dejligbjerg M, Grauslund M, Christensen I, Tjørnelund J, Buhl Jensen P, Sehested M (2008) Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines. Cancer Biomarkers: Section A Disease Markers 4(2): 101-109.
9. Geng L, Cuneo K, Fu A, Tu T, Atadja P, Hallahan D (2006) Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 66(23): 11298-11304.
10. Goodarzi A, Jeggo P, Lobrich M (2010) The influence of heterochromatin on DNA double strand break repair: getting the strong, silent type to relax. DNA Repair (Amst) 9(12): 1273-1282.
11. Kachhap S, Rosmus N, Collis S, Kortenhorst M, Wissing M, Hedayati M, Shabbeer S, Mendonca J, Deangelis J, Marchionni L, Lin J, Hoti N, Nortier J, DeWeese T, Hammers H, Carducci M (2010) Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. Plos One 5(6): e11208
12. Kamrava M, Citrin D, Sproull M, Lita E, Smith S, Crouse N, Cooley-Zgela T, Fine H, Camphausen K (2008) Acute toxicity in a phase II clinical trial of valproic acid in combination with temodar and radiation therapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 72(Suppl): S211
13. Khan O, Fotheringham S, Wood V, Stimson L, Zhang C, Pezzella F, Duvic M, Kerr D, La Thangue N (2010) HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci USA 107(14): 6532-6537.
14. Konsoula Z, Cao H, Velena A, Jung M (2011) Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity. Int J Radiat Oncol Biol Phys 79(5): 1541-1548.
15. Kotian S, Liyanarachchi S, Zelent A, Parvin J (2010) Histone deacetylases 9 and 10 are required for homologous recombination. J Biol Chem 286(10): 7722-7726.
16. Kuribayashi T, Ohara M, Sora S, Kubota N (2010) Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation. Int J Mol Med 25(1): 25-29.
17. Lee J, Choy M, Ngo L, Foster S, Marks P (2010) Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 107(33): 14639-14644.
18. Masoudi A, Elopre M, Amini E, Nagel ME, Ater JL, Gopalakrishnan V, Wolff JE (2008) Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res 28(4C): 2437-2442.
19. Miller K, Tjeertes J, Coates J, Legube G, Polo S, Britton S, Jackson S (2010) Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 17(9): 1144-1151.
20. Munshi A, Kurland J, Nishikawa T, Tanaka T, Hobbs M, Tucker S, Ismail S, Stevens C, Meyn R (2005) Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11(13): 4912-4922.
21. Munshi A, Tanaka T, Hobbs M, Tucker S, Richon V, Meyn R (2006) Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 5(8): 1967-1974.
22. Noguchi H, Yamashita H, Murakami T, Hirai K, Noguchi Y, Maruta J, Yokoi T, Noguchi S (2009) Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr J 56(2): 245-249.
23. Nolan L, Johnson PW, Ganesan A, Packham G, Crabb SJ (2008) Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer 99(5): 689-694.
24. Rassool FV, Tomkinson AE (2010) Targeting abnormal DNA double strand break repair in cancer. Cell Mol Life Sci 67(21): 3699-3710.
25. Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K (2010) Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the pelvic radiation and vorinostat (PRAVO) phase 1 study. Lancet Oncol 11(5): 459-464.
26. Ropero S, Esteller M (2007) The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1(1): 19-25.
27. Shabason JE, Tofilon PJ, Camphausen K (2011) Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med 15(12): 2735-2744.
28. Sharma N, Groselj B, Hamdy F, Kiltie A (2012) The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers. Br J Urol Int; in press
29. Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31(1): 27-36.
30. Spiegel S, Milstien S, Grant S (2012) Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 31(5): 537-551.
31. Thompson L (2012) Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. Mutat Res 751(2): 158-246.
32. Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, De Martino Rodriguez A, Jose-Eneriz ES, Miranda E, Mart?n-Subero JI, Garate L, Blanco-Prieto MJ, Garc?a de Jalon JA, Rio P, Rifon J, Cigudosa JC, Martinez-Climent JA, Roman-Gomez J, Calasanz MJ, Ribera JM, Prosper F (2012) Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia 26(7): 1517-1526.
33. Wagner JM, Hackanson B, Lubbert M, Jung M (2010) Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 1(3-4): 117-136.
34. Williams G, Lees-Miller S, Tainer J (2010) Mre11-Rad50-Nbs1 conformations and the control of sensing, signaling, and effector responses at DNA double-strand breaks. DNA Repair (Amst) 9(12): 1299-1306.
35. Zhang F, Zhang T, Teng Z, Zhang R, Wang J, Mei Q (2009) Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells. Cancer Biol Ther 8(9): 823-831.